Modalis Therapeutics Corporation provides Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2020. For the full year the company forecast operating revenue of ¥1,100 million or over. Operating income of ¥350 million over. Profit attributable to owners of parent of ¥250 million or over. Basic earnings per share of ¥9.63 or over.